Station 24 · Medication review
An 86-year-old on eleven medicines comes with her daughter for the review the pharmacist flagged; she is dizzy, her kidneys are slipping, and the daughter wants nothing stopped.
Reviewed and kept current
Face-to-face consultation · Older adults · Prescribing · Long-term condition · 12-minute case · 3 min reading · Last editorial review: 11 October 2026 · Next scheduled refresh: 11 April 2027 · Clinical content signed by Course Director, 11 October 2026.
Read this as you would outside the room
Read the brief as you would in the examination (RCGP: twelve consultations with simulated patients, each lasting twelve minutes, with 3 minutes' reading at the start of each). There is no reference material. Everything below the brief is folded until the consultation is over.
| Information | |
|---|---|
| Frame | You have 3 minutes to read, then 12 minutes. Face-to-face simulated consultation. Everything below this brief is folded away until the consultation is over. |
| Your role | GP partner at a semi-rural practice, in your consulting room; a double appointment booked for a structured medication review. |
| Patient | Mrs Edna Pargeter, 86. Her daughter, Carol, 58, has come with her. |
| Reason for consultation | Structured medication review, flagged by the practice pharmacist: “eGFR falling; on 11 items; two falls this year; please review.” |
| Format | Face to face in your consulting room with her daughter present. You may examine with her consent. |
Information available
The records extract, printed as it appears. Results carry units and reference ranges.
| Problem list | Hypertension. Type 2 diabetes. Atrial fibrillation. Osteoarthritis. Chronic kidney disease stage 3b. Osteoporosis. Two falls this year (no fracture). Lives with her daughter. Clinical frailty scale 6. |
| Medication | Ramipril 10 mg. Amlodipine 10 mg. Bendroflumethiazide 2.5 mg. Bisoprolol 5 mg. Apixaban 5 mg twice daily. Gliclazide 80 mg twice daily. Metformin 1 g twice daily. Atorvastatin 40 mg. Alendronic acid 70 mg weekly. Co-codamol 30/500, two four times daily. Omeprazole 20 mg. Allergies: none recorded. |
| Bloods, 2 weeks ago | eGFR 34 mL/min/1.73m² (was 44 a year ago). Creatinine 128 micromol/L (45–84). Potassium 5.1 mmol/L (3.5–5.3). HbA1c 50 mmol/mol. Sodium 136. |
| Observations, 2 weeks ago | BP 118/66 sitting. Weight 52 kg (58 kg two years ago). Pulse 56. |
| Falls | February: in the kitchen at night. June: standing from the chair. Emergency department: no fracture; “advised GP medication review”. |
Your task
For the role player and the observer
Open these after the consultation, or during it if you are observing. The role-player script and every marking section are public (D-76): this is practice material, not an examination.
1 · Role-player script — opening line, story, ICE, hidden facts and triggers (examination findings last)
Candidates: do not open until you have consulted.
Persona and manner
- Edna Pargeter, 86; alert, polite, a little deaf, inclined to let Carol speak; you have views when asked directly and a dry humour. You are tired of the tablets and would “happily throw half of them in the bin”, but you will not say so in front of Carol unless asked.
- Carol, 58, her daughter and carer; devoted, anxious, organised; she fills the dosette box and keeps a list; she believes every tablet is keeping her mother alive and fears that stopping any of them is giving up.
Opening line (verbatim)
- “Carol: “The pharmacist said Mum's kidneys are going down and someone needs to look at her tablets. I've brought the list. I don't want anything stopped that's keeping her well, though. She's done brilliantly on these for years.””
The story
- Edna, if asked directly: “I'm dizzy when I stand. Every morning, and after my dinner. I've gone over twice. I hold on to the furniture.”
- Edna: “I'm not hungry. Carol does lovely food and I push it round the plate. My mouth's dry. I'm up three times a night.”
- If asked about hypos: “I go shaky and sweaty before lunch if I'm late with it. Carol gives me a biscuit.” Three or four times a month.
- If asked about pain: the knees ache; the co-codamol “makes me woozy and bungs me up”; you take it because it is in the box.
- If asked about the alendronic acid: you take it standing up on Mondays; it gives you heartburn; you have taken it for nine years.
- If asked about memory: “Not what it was, but I know what's what.” Carol: “She's sharp as a tack.”
- Carol, if the doctor proposes a change: “But her blood pressure's been perfect.” “The diabetes nurse said the sugar must stay down.” “My dad had a stroke; that's why she's on the blood thinner.”
- If asked what matters most: Edna: “Not falling. Staying here with Carol. Getting to the garden.” Carol: “Keeping her safe.”
- If asked, Edna would like fewer tablets; Carol would accept changes if she understood why and if the doctor took the responsibility.
Ideas, concerns and expectations
- Idea: Carol's: the tablets are keeping her mother alive and the kidneys are a separate problem. Edna's: “It's the tablets that make me dizzy.”
- Concern: Carol's: that stopping tablets means giving up on her mother; a stroke like her father. Edna's: falling again; a care home; being a burden.
- Expectation: Carol's: reassurance and the list kept as it is. Edna's: fewer tablets and the dizziness gone.
Impact
- Home: Edna lives with Carol; Carol fills the box; the garden is Edna's pleasure.
- Falls: two this year; the kitchen at night and standing from the chair.
- Food: appetite gone; weight down six kilograms; a dry mouth.
Red flags
- Present: Dizziness on standing with two falls on four blood-pressure-lowering drugs at 118/66; hypos on gliclazide with an HbA1c of 50 at 86; an eGFR of 34 on metformin, ramipril and a thiazide with a potassium of 5.1; an opioid causing drowsiness; nine years of alendronic acid; six kilograms lost.
- Absent: No chest pain, breathlessness or syncope; no bleeding on apixaban; no confusion or delirium; no fracture; no new neurological symptoms.
Hidden facts and their triggers
- The hypos before lunch — released only only if asked directly about shaking, sweating or funny turns; Carol calls them “a bit wobbly”
- That Edna would happily throw half the tablets in the bin — released only only if Edna is asked directly, and what matters most to her is asked
- The heartburn on alendronic acid and the nine years — released only if asked about the bone tablet
- That Carol's father died of a stroke — released only if the doctor raises the apixaban or asks why the blood thinner matters to Carol
- That Carol would accept changes if the doctor took the responsibility — released only if the doctor asks Carol what would make a change acceptable
Behaviour
- Minute 1: Carol presents the list; Edna smiles and says nothing.
- Minute 3, if Edna is asked directly: “I'm dizzy when I stand.”
- Minute 6, if a change is proposed: Carol: “But her blood pressure's been perfect.”
- If the doctor asks Edna what matters most, examines her lying and standing, links the dizziness and the falls to the blood-pressure tablets and the hypos to the gliclazide, explains each change as a way of keeping her at home and in the garden, reduces in steps with a date, keeps the apixaban and explains why, and gives Carol a role and a plan she can follow in the box: Edna: “Thank goodness.” Carol, after a pause: “If you'll write it all down, and we see you again.”
- If the doctor keeps everything because Carol objects: Edna looks at the floor.
- If the doctor stops everything at once: Carol: “That's half her tablets. Are you sure?”
- If the doctor speaks only to Carol: Edna stops answering.
Examination findings, if the candidate states what they would examine and why
- If the candidate explains and asks: blood pressure lying 126/70, standing at one minute 96/58 with dizziness; pulse 54, irregular; weight 52 kg; dry mouth; no ankle swelling; chest clear; heart sounds normal; capillary glucose 6.1 at 11 a.m.; she needs her hands to rise from the chair; a timed up-and-go of 19 seconds.
2 · Examiner mark sheet — generic SCA scheme plus the key facts for this case
Domain grades — with the key facts that earn a clear pass at this station
| Domain (RCGP wording) · key facts for this case | CF (0) | F (1) | P (2) | CP (3) | Score |
|---|---|---|---|---|---|
1 · Data gathering and diagnosis
| ☐ | ☐ | ☐ | ☐ | /3 |
2 · Clinical management and medical complexity (×1.5)
| ☐ (0) | ☐ (1.5) | ☐ (3) | ☐ (4.5) | /4.5 |
3 · Relating to others
| ☐ | ☐ | ☐ | ☐ | /3 |
| Case total | /10.5 |
Global rating (recorded, not added to the total): ☐ Fail ☐ Bare Fail ☐ Bare Pass ☐ Pass
The domain grades (RCGP descriptors): CP clear pass — above the standard of a newly qualified, independent GP · P pass — sufficiently demonstrated at the standard · F fail — insufficiently demonstrated at the standard · CF clear fail — clearly demonstrated below the standard.
The RCGP grades each domain CF, F, P or CP and weights clinical management and medical complexity against the other two domains; the examination's maximum is 126 over twelve cases, which is 10.5 per case. The RCGP does not publish the mark each grade carries. MD Acumen's training sheet uses CF 0 · F 1 · P 2 · CP 3, with clinical management weighted ×1.5 (0 · 1.5 · 3 · 4.5), so that a case is marked out of 10.5 and a twelve-case circuit out of 126. A P in all three domains is 7.0; MD Acumen treats that line as the training standard for a case. The examination's pass mark is set by borderline regression for each diet and is published in the RCGP's diet summary reports; it is not a fixed fraction of 126.
Weighting rationale, in the RCGP's words: “To reflect the capability coverage within the clinical management and medical complexity domain this is weighted in comparison to the other two domains.”
3 · Expanded station standard — what earns a clear pass, pass, fail and clear fail here
Written to the standard of a newly qualified independent GP; the clear-pass row describes practice above that standard. It is a debriefing aid, not a checklist: the grade is a judgement that the essentials, the italic key facts on the mark sheet, were done well, at the patient's pace and in plain language. MD Acumen training standard; the RCGP does not publish case mark sheets.
| Grade | Data gathering and diagnosis | Clinical management and medical complexity | Relating to others |
|---|---|---|---|
| CP | Turns to Edna in the first minute and asks what matters most to her before the list is opened, then reads the list against her symptoms: the dizziness and the four blood-pressure drugs, the hypos and the gliclazide, the kidneys and the metformin and the thiazide, the wooziness and the opioid, the heartburn and the alendronic acid. Measures lying and standing blood pressure in the room. Asks Carol why the blood thinner matters to her. | Deprescribes in a sequence with a date for each step: the thiazide stopped and the ramipril reduced for the postural drop and the potassium, the gliclazide stopped and the metformin reduced for the eGFR, the co-codamol tapered with paracetamol and a topical treatment, the alendronic acid stopped after nine years. Keeps the apixaban at the correct dose and the bisoprolol and says why. Arranges bloods in two weeks, a falls referral, and a review with the written plan. | Keeps Edna at the centre and lets Carol be the carer she is: asks what each of them fears and answers both. Reframes the review as treatment for the falls and the hypos rather than giving up, in words Edna can repeat (“fewer tablets, fewer falls”). Takes responsibility for the changes aloud, so that Carol does not have to. Gives Carol the written plan for the box and a date to come back. Checks what each has understood, separately. |
| P | Asks Edna directly about the dizziness, the falls, hypos, pain, appetite and sleep. Reviews every medicine against the results: the blood pressure of 118/66 on four agents, the hypos on gliclazide, the eGFR of 34 with metformin and a thiazide, the potassium of 5.1, the opioid, the alendronic acid after nine years. Measures lying and standing blood pressure. Asks what matters most to Edna and to Carol. | Stops the thiazide and reduces the ramipril; stops the gliclazide and reduces the metformin dose for the eGFR; tapers the co-codamol with paracetamol and a topical treatment; stops the alendronic acid after nine years with a bone-health review; keeps the apixaban and the bisoprolol with the reasons. Bloods in two weeks; a falls-prevention referral. A written plan for the dosette box; a safety-net for a fall, a hypo, confusion or bleeding; review in two weeks. | Speaks to Edna, not only to Carol. Reframes stopping tablets as treatment rather than giving up. Answers Carol's fear of a stroke by keeping the apixaban and saying why. Explains each change simply; gives Carol the written plan and a role. Shares the decision and checks understanding. |
| F | Conducts the review with Carol and the list, and never asks Edna how she is. Does not ask about hypos, or asks and accepts “a bit wobbly”. Does not measure lying and standing blood pressure. Does not read the eGFR trend or the potassium. Does not ask what matters most to Edna. | Keeps everything because Carol objects. Or stops everything at once with no sequence and no date. Stops the apixaban because she falls. Leaves the gliclazide and the hypos. Leaves metformin at full dose at an eGFR of 34. No bloods arranged. No written plan. No review. | Talks only to Carol, so that Edna stops answering. Argues with Carol rather than asking what she fears. Uses deprescribing, orthostatic and frailty as labels. Does not take responsibility for the changes, so Carol has to. Does not check what Edna has understood. |
| CF | No history from the patient; the list reviewed as a list with no link to the dizziness, the falls, the hypos or the kidneys; no examination; the results not read. Or a consultation in which Edna says “I'm dizzy when I stand” and no one responds. | Unsafe: four blood-pressure drugs, gliclazide with hypos and full-dose metformin left unchanged at an eGFR of 34 in a woman who has fallen twice; or the apixaban stopped for falls while the hypotensive drugs continue; or everything stopped at once with no plan, no bloods and no review. She leaves to fall again, or to have a stroke. | Patronising to Edna, combative with Carol, or collusive with the list; speaks about Edna as if she were not there; ends with no agreement and Edna looking at the floor. No partnership with either of them, and no one taking responsibility for the plan. |
Where candidates lose this station
- Reviewing the list with Carol and never asking Edna what matters most or how she feels when she stands (statement R3)
- Keeping every medicine because Carol objects, so that the dizziness, the hypos and the kidneys continue (statement C5)
- Stopping the apixaban because she falls, while the four blood-pressure drugs that cause the falls continue (statement D8)
What the examiner is listening for in the last four minutes
By 8:00 the working assessment should have been stated: the medicines are causing the dizziness, the falls and the hypos, and the kidneys are being over-treated. The examiner is listening for: each change with its reason and its date (the thiazide, the ramipril, the gliclazide, the metformin dose, the co-codamol, the alendronic acid); the apixaban and the bisoprolol kept and why; the bloods in two weeks and the falls referral; the written plan for the box and Carol's role; a safety-net for a fall, a hypo, confusion or bleeding; the review in two weeks; and Edna's own words, then Carol's, on what will change this week.
4 · RCGP feedback statements — where underperformance was identified — with case-specific examples
The ten statements below are postulated: the feedback an examiner would most likely attach at this station, chosen from the RCGP's standardised list of 26 feedback statements that applies to every SCA case and spans the three marking domains (Data Gathering and Diagnosis; Clinical Management and Medical Complexity; Relating to Others). They are a prediction from the case content, its complexity and the marks that matter, not an examiner's record: any statement on the full list can be attached to any case, and feedback plays no part in the mark. Record the statements that applied in the practice log.
| RCGP feedback statement (postulated top ten) | Underperformance it signals (generic) | Station-specific example |
|---|---|---|
| D1 · Data gathering was insufficient to enable safe assessment of the condition/situation Data gathering and diagnosis · Data gathering and interpretation | History too thin to decide safely: the presenting problem not characterised, the essential negatives not asked. |
|
| D2 · Existing information about the case was insufficiently utilised Data gathering and diagnosis · Data gathering and interpretation; Organisation, management and leadership | The records, results or the referral note not read or not used; questions asked that the notes already answer. |
|
| D6 · The implications of relevant findings identified during the data gathering were insufficiently recognised or understood Data gathering and diagnosis · Data gathering and interpretation | A finding or result is elicited but its meaning is not recognised or not followed up. |
|
| D8 · Decision-making or diagnosis was illogical, incorrect or incomplete Data gathering and diagnosis · Making diagnosis/decisions; Clinical management; Managing medical complexity | The conclusion does not follow from the data, is wrong, or stops short of a working diagnosis. |
|
| C2 · The management plan relating to prescribing of medication was inappropriate or not reflective of current practice Clinical management and medical complexity · Clinical management | A drug started, continued or stopped against current guidance, or without the checks it needs. |
|
| C3 · The management plan relating to investigations was inappropriate or not reflective of current practice Clinical management and medical complexity · Clinical management | Investigations ordered without purpose, omitted when needed, or not explained. |
|
| C5 · The plan relating to the medical management of risk was inadequate or inappropriate Clinical management and medical complexity · Clinical management; Organisation, management and leadership | Clinical risk left unmanaged: no plan for the thing that could go wrong, or the risk not weighed. |
|
| R3 · The circumstances, relevant cultural differences and/or preferences of those involved were insufficiently responded to Relating to others · Communication and consultation skills; Practising holistically, promoting health and safeguarding; Community orientation | The person's circumstances, culture or preferences not responded to in the plan. |
|
| R4 · Explanations were inadequately shared or adapted for the person's needs Relating to others · Communication and consultation skills | Explanation in jargon, at the wrong pace, or not adapted to the person's level and concerns. |
|
| R8 · Teamwork and/or understanding of others' roles was insufficiently recognised or responded to Relating to others · Working with colleagues and in teams | Colleagues' roles not understood; the team not used; the handover not made. |
|
The full list of 26 statements, with the generic meaning of each, is on the exam and the mark scheme.
5 · Examiner points of fact and guidelines
Points of fact the examiner should have to hand
Each statement is drawn from the named guideline, in its current version, with the date it was checked. The examiner marks against these facts; the candidate is not expected to quote them.
- Offer a structured medication review to people with multimorbidity who are taking many regular medicines, using the person's goals and preferences; consider stopping medicines where the burden outweighs the benefit, particularly in frailty and limited life expectancy, and agree the changes with the person and their carer. NICE — NG56 Multimorbidity: clinical assessment and management, section 1.6, reviewing medicines and other treatments, September 2016, checked 10 Oct 2026
- In people aged 80 and over, a clinic blood pressure target below 150/90 mmHg applies; in frail older people, consider the person's frailty, co-morbidity and postural hypotension when deciding treatment; measure standing blood pressure in people with symptoms of postural hypotension and treat to the standing reading. NICE — NG136 Hypertension in adults: diagnosis and management, section 1.4, treatment targets; section 1.1, measuring blood pressure: postural hypotension, 2019, last updated February 2026, checked 10 Oct 2026
- In adults with type 2 diabetes, individualise the HbA1c target and relax it for people who are frail, older or at risk of hypoglycaemia; avoid sulfonylureas where hypoglycaemia is a particular risk; review metformin dose when eGFR is below 45 and stop it below 30. NICE — NG28 Type 2 diabetes in adults: management, section 1.6, HbA1c targets; section 1.7, drug treatment: metformin and renal impairment, 2015, last updated February 2026, checked 10 Oct 2026
- Do not withhold anticoagulation in atrial fibrillation solely because of a risk of falls; apixaban is reduced to 2.5 mg twice daily when two of age 80 or over, weight 60 kg or less, or creatinine 133 micromol/L or more are present; a woman of 86 weighing 52 kg meets two criteria. NICE — NG196 Atrial fibrillation: diagnosis and management, section 1.6, anticoagulation: falls; (dose from the BNF apixaban monograph), 2021, last updated June 2021, checked 10 Oct 2026
- Alendronic acid: review the need for continued treatment after five years (three years for zoledronic acid); in people at lower risk consider a treatment break with reassessment of fracture risk; in people at high risk continue up to ten years and then review. NICE CKS — Osteoporosis: prevention of fragility fractures, management: duration of bisphosphonate treatment and treatment breaks, current online version, checked 10 Oct 2026
- Opioids are not recommended for osteoarthritis pain and cause drowsiness, constipation and falls in older people; when withdrawing a long-term opioid, reduce gradually and agree the plan with the person; offer paracetamol and a topical NSAID for knee pain. NICE — NG226 Osteoarthritis in over 16s: diagnosis and management, section 1.4, pharmacological management, October 2022, checked 10 Oct 2026
- The STOPP criteria list, among others: a thiazide with hypokalaemia or hyponatraemia, a sulfonylurea with recurrent hypoglycaemia, an ACE inhibitor with hyperkalaemia, any drug that causes postural hypotension in a person with falls, and long-term opioids as first-line for mild to moderate pain; the START criteria list what should be added. O'Mahony D et al. (European Geriatric Medicine) — STOPP/START criteria for potentially inappropriate prescribing in older people: version 3, STOPP sections B, J and K, 2023, checked 10 Oct 2026
- Offer a multifactorial falls assessment to older people who have had two or more falls, including a medication review targeting drugs that lower blood pressure or sedate, strength and balance training, and a home hazard assessment. NICE — NG249 Falls: assessment and prevention in older people and people 50 and over at higher risk, section 1.2, multifactorial falls risk assessment; section 1.3, interventions, April 2025, checked 10 Oct 2026
- The ADA Standards of Care (2025), Older adults, set glycaemic goals by health status: for older adults in good health an HbA1c below 7.0 to 7.5 per cent (53 to 58 mmol/mol); for complex or intermediate health (several coexisting conditions, mild cognitive impairment or impaired instrumental activities of daily living) below 8.0 per cent (64 mmol/mol); for very complex or poor health, avoid reliance on HbA1c and avoid hypoglycaemia. Sulfonylureas are avoided because of hypoglycaemia; over-treatment is common, and de-intensification is recommended where it reduces hypoglycaemia and polypharmacy. ADA — Standards of Care in Diabetes 2025: section 13, Older adults, glycaemic goals by health status; treatment de-intensification and simplification, 2025, checked 10 Oct 2026
- NG5 defines a medication review as a structured, critical examination of a person's medicines, with the aim of reaching agreement with the person about treatment, optimising the impact of medicines, minimising medication-related problems and reducing waste; it is offered to people taking multiple medicines, people with long-term conditions and older people. The review covers the person's and carer's views and understanding, every prescribed and over-the-counter medicine, whether each remains clinically appropriate, monitoring needed and adverse effects; the outcome is recorded and shared. NICE — NG5 Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes, section 1.3, medication review, March 2015, checked 10 Oct 2026
- An eGFR of 30 to 44 is CKD category G3b. Accelerated progression is a sustained fall in eGFR of 25 per cent or more with a change in category within a year, or a sustained fall of 15 or more a year; a fall from 44 to 34 in a year approaches the first threshold and is repeated with a urine albumin-to-creatinine ratio. On an ACE inhibitor, potassium and eGFR are monitored: not started if potassium exceeds 5.0 mmol/L, stopped at 6.0 or more. NICE — NG203 Chronic kidney disease: assessment and management, section 1.1, classification and defining progression; section 1.6, pharmacotherapy: ACE inhibitors and potassium, August 2021, checked 10 Oct 2026
- NG56 says that when assessing for frailty in primary care the GP may use an informal assessment of gait speed (more than five seconds to walk four metres, or below 0.8 metres a second), self-reported health status, a validated tool such as PRISMA-7 (a score of 3 or more), or the timed up-and-go test (more than 12 seconds); a woman who needs her hands to rise from a chair and takes 19 seconds meets this threshold, and frailty so identified is the basis for the tailored approach NG56 describes. NICE — NG56 Multimorbidity: clinical assessment and management, section 1.2, identifying people who may benefit from a tailored approach: frailty, September 2016, checked 10 Oct 2026
- The Older adults Topic Guide expects the GP to recognise and grade frailty, to lead a structured medication review and deprescribe safely with a sequence and a date for each step, to assess falls and postural hypotension, to keep the older person's own priorities at the centre while involving the carer, to assess capacity where a decision is in doubt, and to arrange monitoring and follow-up after any change in medicines. RCGP — GP curriculum: Older adults, Topic Guide: frailty; polypharmacy and medication review; falls; working with carers, 2025 curriculum (Being a GP), checked 10 Oct 2026
Working references for this station
13 statements, 774 words. Every statement is signed by the Course Director before it is published; a station whose facts have changed since signature carries no signature line until it is signed again.
This case's topic and its signed Golden Triangle, for review after the station.
Golden Triangle
Falls in older people: assessment and prevention
Knowledge Amber · Evidence Amber · Real-world Red
Not yet at the Equinox · UK (NHS England) · as of 8 October 2026 · How the triangle works
6 · RCGP curriculum tags for this case
| RCGP curriculum (2025) | This case |
|---|---|
| Topic Guide(s) | Older adults · Continuity and quality of care, safety and prescribing · People with long-term conditions including cancer |
| Core capabilities | Medical complexity · Clinical management · Communicating and consulting · Data gathering and interpretation |
| SCA Clinical Experience Group(s) | Older adults, including frailty and people at the end of life · Prescribing · Long-term condition, including cancer, multi-morbidity, and disability |
| AKT blueprint clinical area | Therapeutics, including indications for prescribing and adverse effects (focused representation) |
| Case type | long-term condition |
| Modality | face-to-face |
7 · My marks and reflection — practice log form
Record your three domain grades, your case total out of 10.5, your global rating, the RCGP feedback statements that applied, and what you will keep and change. The form is already labelled with this case and its web address; a copy of your entry is emailed to you, so your practice log builds up in your inbox and can be downloaded.
Record my marks and reflection for SCA-24
Revision link for this case: mdacumen.com/sca-station24-medication-review
Independence & scope. Formative training material from MD Acumen Ltd; not a prediction of exam performance. Not affiliated with, endorsed by, or delivered on behalf of the Royal College of General Practitioners; the marking domains and feedback statements are the RCGP's published ones, and every descriptor on this page is an Acumen training tool calibrated to them. Clinical content reflects UK guidance at the date of editorial review — always check the current guideline. All patients are fictional.
Continue through the course

© 2026 MD Acumen Ltd · Registered in England and Wales · Company no. 16538952 · ICO registration ZC105897